Docstoc

Urinary Incontinence UI Therapeutics Pipeline Assessment and

Document Sample
Urinary Incontinence UI Therapeutics Pipeline Assessment and Powered By Docstoc
					Urinary Incontinence (UI) Therapeutics -
Pipeline Assessment and Market Forecasts
to 2018




http://www.askchinareport.com   Page 1 of 15
1、Table of Contents



【Report Price】:Single user price USD3500.00

                      Site License Price USD7000.00

                      Enterprisewide Price $ (Global Site License) USD10500.00



【File Name】:GDHC404PRT



【Summary】:



Company, the industry analysis specialist, has released its new report, “Urinary Incontinence (UI) The
rapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of inf
ormation and analysis on the global Urinary Incontinence Therapeutics market. The report identifies th
e key trends shaping and driving the global Urinary Incontinence Therapeutics market. The report also
 provides insights on the prevalent competitive landscape and the emerging players expected to signifi
cantly alter the market positioning of the current market leaders. Most importantly, the report provides
 valuable insights on the pipeline products within the global Urinary Incontinence Therapeutics sector.
 This report is built using data and information sourced from proprietary databases, primary and secon
dary research and in-house analysis by Company’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Urinary Incontinence Therap
eutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Urinary Incontine
nce Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being devel
oped and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic class
es.



  http://www.askchinareport.com                                                    Page 2 of 15
- Analysis of the current and future competition in the seven key countries Urinary Incontinence Thera
peutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently r
esearched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs an
d the implications for the Urinary Incontinence Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Urinary Incontinence Therapeutics m
arket

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline produ
cts and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Urinary Inco
ntinence Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segm
ents and companies likely to impact the global Urinary Incontinence Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and b
y analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strat
egies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that pre
sent maximum opportunities for consolidations, investments and strategic partnerships.

- What’s the next big thing in the global Urinary Incontinence Therapeutics market landscape? – Identi
fy, understand and capitalize.



【Table of Contents】:



1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Urinary Incontinence (UI) Therapeutics - Introduction 6

2.1 Overview 6


  http://www.askchinareport.com                                                      Page 3 of 15
2.2 Types of UI 6

2.3 Epidemiology 7

2.4 Etiology 8

2.5 Risk Factors 8

2.6 Pathophysiology 9

2.7 Diagnosis of UI 10

2.8 Treatment and Management Pattern 11

2.8.1 Behavioral Techniques 11

2.8.2 Physical Therapy 11

2.8.3 Medical Devices 11

2.8.4 Pharmacological 12

2.8.5 Interventional therapies 12

2.8.6 Surgical 12

2.9 Company Report Guidance 14

3 UI Therapeutics - Market Characterization 15

3.1 UI Therapeutics Market Size (2005-2010) - Global 15

3.2 UI Therapeutics Market Forecast (2010-2018) - Global 17

3.3 UI Therapeutics Market Size (2005-2010) - The US 19

3.4 UI Therapeutics Market Forecast (2010-2018) - The US 20

3.5 UI Therapeutics Market Size (2005-2010) - France 21

3.6 UI Therapeutics Market Forecast (2010-2018) - France 22

3.7 UI Therapeutics Market Size (2005-2010) - Germany 24

3.8 UI Therapeutics Market Forecast (2010-2018) - Germany 25

3.9 UI Therapeutics Market Size (2005-2010) - Italy 26

3.10 UI Therapeutics Market Forecast (2010-2018) - Italy 27

3.11 UI Therapeutics Market Size (2005-2010) - Spain 29

3.12 UI Therapeutics Market Forecast (2010-2018) - Spain 30


  http://www.askchinareport.com                                Page 4 of 15
3.13 UI Therapeutics Market Size (2005-2010) - The UK 31

3.14 UI Therapeutics Market Forecast (2010-2018) - The UK 32

3.15 UI Therapeutics Market Size (2005-2010) - Japan 34

3.16 UI Therapeutics Market Forecast (2010-2018) - Japan 35

3.17 Drivers and Barriers for the UI Therapeutics Market 36

3.17.1 Drivers for the UI Therapeutics Market 36

3.17.2 Barriers for the UI Therapeutics Market 36

3.18 Key Events Impacting the Future Market 37

3.19 Opportunity and Unmet Need 37

3.20 Key Takeaway 38

4 UI Therapeutics - Competitive Assessment 39

4.1 Overview 39

4.2 Strategic Competitor Assessment 39

4.3 Product Portfolio for Major Marketed Products in the UI Therapeutics Market 40

4.3.1 Botox (onabotulinumtoxinA) 40

4.3.2 Detrol/Detrol LA (tolterodine tartrate) 41

4.3.3 Ditropan XL (Oxybutynin chloride) 42

4.3.4 Enablex (darifenacin) 43

4.3.5 Sanctura XR (trospium chloride) 45

4.3.6 Toviaz (fesoterodine fumarate) 45

4.3.7 VESIcare (solifenacin succinate) 47

4.4 Key Takeaway 47

5 UI Therapeutics - Pipeline Assessment 48

5.1 Overview 48

5.2 Strategic Pipeline Assessment 48

5.3 UI Pipeline - Pipeline by Phases of Development 48

5.3.1 UI Therapeutics - Pre-registration Pipeline 48


  http://www.askchinareport.com                                                 Page 5 of 15
5.3.2 UI Therapeutics - Phase III Pipeline 49

5.3.3 UI Therapeutics - Phase II Pipeline 49

5.3.4 UI Therapeutics - Phase I/II Pipeline 50

5.3.5 UI Therapeutics - Phase I Pipeline 50

5.3.6 UI Therapeutics - Preclinical Pipeline 50

5.3.7 UI Therapeutics - Discovery Pipeline 51

5.4 UI Therapeutics Pipeline by Mechanism of Action 51

5.5 UI Technology Trends Analytical Framework 52

5.6 UI Therapeutics - Promising Drugs under Clinical Development 53

5.7 Molecule Profile for Promising Drugs under Clinical Development 54

5.7.1 Anturol gel (oxybutynin) 54

5.7.2 DR-3001 (oxybutynin vaginal ring) 54

5.7.3 HOB-294 (oxybutynin transdermal patch) 55

5.7.4 RCD 1 55

5.7.5 YM178 (mirabegron) 56

5.8 Key Takeaway 56

6 UI Therapeutics - Clinical Trials Mapping 57

6.1 Clinical Trials by Country (US, EU5 and Japan) 57

6.2 Clinical Trials by Phase 58

6.3 Clinical Trials by Trial Status 59

6.4 Overall Sponsors 60

6.5 Prominent Sponsors 61

6.6 Top Companies Participating in UI Therapeutics Clinical Trials 62

7 UI Therapeutics - Strategic Assessment 63

7.1 Future Market Competition Scenario 63

8 UI Therapeutics - Future Players 64

8.1 Introduction 64


  http://www.askchinareport.com                                          Page 6 of 15
8.2 Allergan, Inc. 64

8.2.1 Company Overview 64

8.2.2 Financial Overview 64

8.2.3 Business Description 65

8.2.4 UI Therapeutics Pipeline 66

8.3 Antares Pharma, Inc. 67

8.3.1 Company Overview 67

8.3.2 Business Overview 67

8.3.3 Financial Overview 68

8.3.4 UI Therapeutics Pipeline 68

8.4 Astellas Pharma Inc. 68

8.4.1 Company Overview 68

8.4.2 Financial Overview 68

8.4.3 Business Description 68

8.4.4 UI Therapeutics Pipeline 69

8.5 HRA Pharma, SA 70

8.5.1 Company Overview 70

8.5.2 UI Therapeutics Pipeline 70

8.6 Hisamitsu Pharmaceutical Co., Inc. 70

8.6.1 Company Overview 70

8.6.2 Financial Overview 70

8.6.3 UI Therapeutics Pipeline 70

8.7 Teva Pharmaceutical Industries Limited 71

8.7.1 Company Overview 71

8.7.2 Financial Overview 71

8.7.3 Business Overview 71

8.7.4 UI Therapeutics Pipeline 73


  http://www.askchinareport.com                 Page 7 of 15
8.7.5 Other Companies in the UI Therapeutics market 73

9 UI Therapeutics - Licensing and Partnership Deals 77

10 UI Therapeutics - Appendix 79

10.1 Definitions 79

10.2 Abbreviations 79

10.3 Methodology 80

10.3.1 Coverage 80

10.3.2 Secondary Research 80

10.3.3 Forecasting 81

10.3.4 Primary Research 83

10.3.5 Expert Panel Validation 84

10.4 Contact Us 84

10.5 Disclaimer 84

10.6 Bibliography 85



【List of Tables】:



1.1 List of Tables

Table 1: UI Epidemiology in Major Markets, 2011 7

Table 2: UI Therapeutics Market, Global, Revenue ($bn), 2005-2010 15

Table 3: UI Therapeutics Market, Global, Forecasts ($bn), 2010-2018 18

Table 4: UI Therapeutics Market, The US, Revenue ($bn), 2005-2010 19

Table 5: UI Therapeutics Market, The US, Forecasts ($bn), 2010-2018 21

Table 6: UI Therapeutics Market, France, Revenue ($m), 2005-2010 22

Table 7: UI Therapeutics Market, France, Forecasts ($m), 2010-2018 23

Table 8: UI Therapeutics Market, Germany, Revenue ($m), 2005-2010 24

Table 9: UI Therapeutics Market, Germany, Forecasts ($m), 2010-2018 26


  http://www.askchinareport.com                                          Page 8 of 15
Table 10: UI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27

Table 11:UI Therapeutics Market, Italy, Forecasts ($m), 2010-2018 28

Table 12: UI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29

Table 13: UI Therapeutics Market, Spain, Forecasts ($m), 2010-2018 31

Table 14: UI Therapeutics Market, The UK, Revenue ($m), 2005-2010 32

Table 15: UI Therapeutics Market, the UK, Forecasts ($m), 2010-2018 33

Table 16: UI Therapeutics Market, Japan, Revenue ($m), 2005-2010 34

Table 17: UI Therapeutics Market, Japan, Forecasts ($m), 2010-2018 36

Table 18: Clinical Study Details of Detrol LA 41

Table 19: Clinical Study Details of Ditropan XL 42

Table 20: Clinical Study Details of Enablex, 2011 44

Table 21: Clinical Study Details of Toviaz, 2011 46

Table 22: UI Therapeutics - Pre-registration Pipeline, 2011 48

Table 23: UI Therapeutics - Phase III Pipeline, 2011 49

Table 24: UI Therapeutics - Phase II Pipeline, 2011 49

Table 25: UI Therapeutics - Phase I/II Pipeline, 2011 50

Table 26: UI Therapeutics - Phase I Pipeline, 2011 50

Table 27: UI Therapeutics - Preclinical Pipeline, 2011 50

Table 28: UI Therapeutics - Discovery Pipeline, 2011 51

Table 29: UI Therapeutics - Promising Drugs Under Clinical Development, 2011 53

Table 30: UI Therapeutics - Clinical Trials by Country, 2011 57

Table 31: UI Therapeutics - Clinical Trials by Phase, 2011 58

Table 32: UI Therapeutics - Clinical Trials by Status, 2011 59

Table 33: UI Therapeutics - Overall Sponsors, 2011 60

Table 34: UI Therapeutics - Prominent Sponsors, 2011 61

Table 35: UI Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 62

Table 36: Allergan, Inc. - UI Therapeutics Pipeline, September 2011 66


  http://www.askchinareport.com                                                  Page 9 of 15
Table 37: Antares Pharma, Inc.- UI Therapeutics Pipeline, September 2011 68

Table 38: Astellas Pharma Inc.- UI Therapeutics Pipeline , September 2011 69

Table 39: HRA Pharma, SA - UI Therapeutics Pipeline , September 2011 70

Table 40: Hisamitsu Pharmaceutical Co., Inc., - UI Therapeutics Pipeline , September 2011 70

Table 41: Teva Pharmaceutical Industries Limited - UI Therapeutics Pipeline , September 2011 73

Table 42: UI Therapeutics market - Other Future Players, 2011 73

Table 43: UI Therapeutics, Global, Deals, 2011 77



【List of Figures】:



1.2 List of Figures

Figure 1: Types of Urinary Incontinence 6

Figure 2: Distribution of Different Types of Incontinence 7

Figure 3: Pathophysiology of Micturition 9

Figure 4: Pathophysiological Features of Different Types of Incontinence 10

Figure 5: Treatment Algorithm for Urinary Incontinence 13

Figure 6: UI Therapeutics Market, Global, Revenue ($bn), 2005-2010 15

Figure 7: UI Therapeutics, Market Share ($m, %), 2010 16

Figure 8: UI Therapeutics Market, Global, Forecasts ($bn), 2010-2018 17

Figure 9: UI Therapeutics, Market Share ($m, %), 2018 18

Figure 10: UI Therapeutics Market, The US, Revenue ($bn), 2005-2010 19

Figure 11: UI Therapeutics Market, The US, Forecasts ($bn), 2010-2018 20

Figure 12: UI Therapeutics Market, France, Revenue ($m), 2005-2010 21

Figure 13: UI Therapeutics Market, France, Forecast ($m), 2010-2018 23

Figure 14: UI Therapeutics Market, Germany , Revenue ($m), 2005-2010 24

Figure 15: UI Therapeutics Market, Germany , Forecast ($m), 2010-2018 25

Figure 16: UI Therapeutics Market, Italy, Revenue ($m), 2005-2010 26


  http://www.askchinareport.com                                                 Page 10 of 15
Figure 17: UI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28

Figure 18: UI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29

Figure 19: UI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30

Figure 20: UI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31

Figure 21: UI Therapeutics Market, The UK, Forecast ($m), 2010-2018 33

Figure 22: UI Therapeutics Market, Japan, Revenue ($m), 2005-2010 34

Figure 23: UI Therapeutics Market, Japan, Forecast ($m), 2010-2018 35

Figure 24: UI Therapeutics, Key Events Impacting Future Market, 2011 37

Figure 25: Opportunity and Unmet Need in the UI Therapeutics Market, 2011 38

Figure 26: Strategic Competitor Assessment of the Major Marketed Products for UI, 2011 39

Figure 27: UI Therapeutics Pipeline by Phase of Development, 2011 48

Figure 28: UI Therapeutics Market - Clinical Pipeline by Mechanism Of Action, 2011 51

Figure 29: Technology Trends Analytical Framework, 2011 52

Figure 30: Technology Trends Analytical Framework - Description, 2011 53

Figure 31: UI Therapeutics - Clinical Trials by Country, 2011 57

Figure 32: UI Therapeutics - Clinical Trials by Phase, 2011 58

Figure 33: UI Therapeutics - Clinical Trials by Status, 2011 59

Figure 34: UI Therapeutics - Overall Sponsors, 2011 60

Figure 35: UI Therapeutics - Prominent Sponsors, 2011 61

Figure 36: UI Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 62

Figure 37: UI Therapeutics, Strategic Assessment, 2011 63

Figure 38: UI Therapeutics Market - Clinical Pipeline by Company , 2011 64

Figure 39: Company Market Forecasting Model 83



Company Web Site:http://www.askchinareport.com/




  http://www.askchinareport.com                                                  Page 11 of 15
URL of the Report:

http://www.askchinareport.com/reports/2011/11/181433349670.shtml


2、Company Profile

China Market Research Reports and Consulting services Platform, affiliated with askci.com Group
headquartered in Shenzhen, is one of the largest professional market intelligence and
investment consulting firm in China.


askchinareport provides customers with professional market intelligence, a wide range of
business and industry analysis, investment consulting, strategic M&A and IPO advisory
services.


·    Global Perspective with Local Knowledge


Understanding and analyzing Chinese markets is an urgent and demanding task today.
askchinareport is a leading market intelligence firms in China, committed to answering
your toughest questions to develop insights and strategic growth plans in Chinese market.


Integrating global research methodologies with local know-how, our team of analysts
conducts customized, objective, and argument-sufficient research to help clients to
understand how to grow strategically and take advantage of opportunities with actionable
initiatives. Our analysts' deep business and industry knowledge allows us to provide
superior and targeted reports, return-on-investment-driven results and workable plans for
our clients.


·    Latest Database and Comprehensive Research Platform


askchinareport has a quick and easy access to the latest database and comprehensive
research platform which are developed in our follow-up studies for more than 10 years
and are updated time to time. askchinareport also innovates and develops specific analysis
models and methods according to different industries.


We pride ourselves on our flexibility in the face of changing market conditions and our


    http://www.askchinareport.com                                           Page 12 of 15
overarching commitment to accurate, honest and objective market intelligence, which are
essential and vital to keep abreast of market and industry trends, understand contributing
factors of economic growth and seize long-term growth opportunities.


·    Membership and Partnership of Authorities


askchinareport has access to top interviews with state ministries and government
departments to provide customers with authority statements and comprehensive industrial
policy guiding.


askchinareport is a member of China Marketing Research Association (CMRA), which is
an academic organization committed to studying Chinese economic development,
composed of Chinese academic circle, government departments and leading firms


askchinareport establishes long-term partnerships with National Statistical Bureau,
industry associations, professional research institutions, credit investigation companies,
data centers and data corporations, which provide us thorough investigations, accurate
data and latest information.


Furthermore, our strategic partners also include numerous fund and securities companies,
PE and VC agencies, law and accounting firms, which exchange different views and
insights in business and economy with us and help us to widen our horizons and enrich
our knowledge.


·    Various Client and Good Reputation


Our clients come from a variety of industries, and they all have different needs. Some
are fortune 500 companies with decades of experience in an industry; others are small
and media-size enterprises just starting to get a foothold. We work with large foreign
groups and private equity firms seeking to invest in China. We also help domestic
companies to become global players.


If you need to research China's industry and market, know your Chinese suppliers or
partners,We can help you !



    http://www.askchinareport.com                                       Page 13 of 15
Report Title   Urinary Incontinence (UI) Therapeutics - Pipeline
               Assessment and Market Forecasts to 2018
Published      Nov/2011
Version        PDF Electronic
Price          0 / copy
Email          yu@askci.com


Report Order
Company                                          Department

Contact Person                                   Tel No.

Address                                          Mobile

E-mail                                           Fax
Report Title:“Urinary Incontinence (UI) Therapeutics - Pipeline Assessment
and Market Forecasts to 2018”
Version :PDF Electronic

Payment:    □Bank

Quantity:           copy

Version :PDF Electronic                /copy


Total Amount


Date of Payment
                      Beneficiary:QF Information Consulting Co., Ltd
                      Beneficiary NO:40000 2111 99000 21558
Bank Account Number
                      Bank Name:The Industrial And Commercial Bank of China Shenzhen
 (USD Account)
                      Branch
                      SWIFT:ICBKCNBJSZN

                      Tel:086-755-25407713     Fax:086-755-25407715
     Contact
                      E-mail:yu@askci.com
   Information
                      Address: Room01,28F,Jintong Building,No.1058,,Aiguo Road,



 http://www.askchinareport.com                                        Page 14 of 15
                                Luohu District, Shenzhen, Guangzhou Province, China

                    Zip code:518000

                    Web Site:http://www.askchinareport.com

    Remarks         Please fill the order and fax to our company ,than we will mail
                    the Invoice after receiving the payment .




http://www.askchinareport.com                                       Page 15 of 15

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:3
posted:12/29/2011
language:English
pages:15